當(dāng)前位置：首頁(yè) SCI期刊 SCIE期刊醫(yī)學(xué) 中科院4區(qū) JCRQ3 期刊介紹(非官網(wǎng))

TrialsSCIE

國(guó)際簡(jiǎn)稱：TRIALS 參考譯名：試驗(yàn)

中科院分區(qū)
4區(qū)
CiteScore分區(qū)
Q2
JCR分區(qū)
Q3

基本信息：: ISSN：1745-6215; E-ISSN：1745-6215; 是否OA：開(kāi)放; 是否預(yù)警：否; TOP期刊：否

出版信息：: 出版地區(qū)：ENGLAND; 出版商：BioMed Central; 出版語(yǔ)言：English; 出版周期：Bimonthly; 出版年份：2000; 研究方向：醫(yī)學(xué)-醫(yī)學(xué)：研究與實(shí)驗(yàn)

評(píng)價(jià)信息：: 影響因子：2; H-index：64; CiteScore指數(shù)：3.8; SJR指數(shù)：0.812; SNIP指數(shù)：0.733

發(fā)文數(shù)據(jù)：: Gold OA文章占比：99.89%; 研究類文章占比：98.32%; 年發(fā)文量：773; 自引率：0.04; 開(kāi)源占比：0.9971; 出版撤稿占比：0; 出版國(guó)人文章占比：0.08; OA被引用占比：1

投稿咨詢加急見(jiàn)刊

英文簡(jiǎn)介期刊介紹 CiteScore數(shù)據(jù) 中科院SCI分區(qū) JCR分區(qū) 發(fā)文數(shù)據(jù) 常見(jiàn)問(wèn)題

英文簡(jiǎn)介Trials期刊介紹

Trials is an open access, peer-reviewed, online journal that will encompass all aspects of the performance and findings of randomized controlled trials. Trials will experiment with, and then refine, innovative approaches to improving communication about trials. We are keen to move beyond publishing traditional trial results articles (although these will be included). We believe this represents an exciting opportunity to advance the science and reporting of trials. Prior to 2006, Trials was published as Current Controlled Trials in Cardiovascular Medicine (CCTCVM). All published CCTCVM articles are available via the Trials website and citations to CCTCVM article URLs will continue to be supported.

期刊簡(jiǎn)介Trials期刊介紹

《Trials》自2000出版以來(lái)，是一本醫(yī)學(xué)優(yōu)秀雜志。致力于發(fā)表原創(chuàng)科學(xué)研究結(jié)果，并為醫(yī)學(xué)各個(gè)領(lǐng)域的原創(chuàng)研究提供一個(gè)展示平臺(tái)，以促進(jìn)醫(yī)學(xué)領(lǐng)域的的進(jìn)步。該刊鼓勵(lì)先進(jìn)的、清晰的闡述，從廣泛的視角提供當(dāng)前感興趣的研究主題的新見(jiàn)解，或?qū)彶槎嗄陙?lái)某個(gè)重要領(lǐng)域的所有重要發(fā)展。該期刊特色在于及時(shí)報(bào)道醫(yī)學(xué)領(lǐng)域的最新進(jìn)展和新發(fā)現(xiàn)新突破等。該刊近一年未被列入預(yù)警期刊名單，目前已被權(quán)威數(shù)據(jù)庫(kù)SCIE收錄，得到了廣泛的認(rèn)可。

該期刊投稿重要關(guān)注點(diǎn)：

預(yù)計(jì)審稿時(shí)間：約4月
醫(yī)學(xué)
MEDICINE, RESEARCH & EXPERIMENTAL
SCIE
中科院4區(qū)
非預(yù)警

Cite Score數(shù)據(jù)（2024年最新版）Trials Cite Score數(shù)據(jù)

CiteScore：3.8
SJR：0.812
SNIP：0.733

學(xué)科類別	分區(qū)	排名	百分位
大類：Medicine 小類：Medicine (miscellaneous)	Q2	148 / 398	62%
大類：Medicine 小類：Pharmacology (medical)	Q2	131 / 272	52%

CiteScore 是由Elsevier(愛(ài)思唯爾)推出的另一種評(píng)價(jià)期刊影響力的文獻(xiàn)計(jì)量指標(biāo)。反映出一家期刊近期發(fā)表論文的年篇均引用次數(shù)。CiteScore以Scopus數(shù)據(jù)庫(kù)中收集的引文為基礎(chǔ)，針對(duì)的是前四年發(fā)表的論文的引文。CiteScore的意義在于，它可以為學(xué)術(shù)界提供一種新的、更全面、更客觀地評(píng)價(jià)期刊影響力的方法，而不僅僅是通過(guò)影響因子(IF)這一單一指標(biāo)來(lái)評(píng)價(jià)。

歷年Cite Score趨勢(shì)圖

中科院SCI分區(qū)Trials 中科院分區(qū)

中科院 2023年12月升級(jí)版 綜述期刊：否 Top期刊：否

大類學(xué)科	分區(qū)	小類學(xué)科	分區(qū)
醫(yī)學(xué)	4區(qū)	MEDICINE, RESEARCH & EXPERIMENTAL 醫(yī)學(xué)：研究與實(shí)驗(yàn)	4區(qū)

中科院分區(qū)表 是以客觀數(shù)據(jù)為基礎(chǔ)，運(yùn)用科學(xué)計(jì)量學(xué)方法對(duì)國(guó)際、國(guó)內(nèi)學(xué)術(shù)期刊依據(jù)影響力進(jìn)行等級(jí)劃分的期刊評(píng)價(jià)標(biāo)準(zhǔn)。它為我國(guó)科研、教育機(jī)構(gòu)的管理人員、科研工作者提供了一份評(píng)價(jià)國(guó)際學(xué)術(shù)期刊影響力的參考數(shù)據(jù)，得到了全國(guó)各地高校、科研機(jī)構(gòu)的廣泛認(rèn)可。

中科院分區(qū)表 將所有期刊按照一定指標(biāo)劃分為1區(qū)、2區(qū)、3區(qū)、4區(qū)四個(gè)層次，類似于“優(yōu)、良、及格”等。最開(kāi)始，這個(gè)分區(qū)只是為了方便圖書管理及圖書情報(bào)領(lǐng)域的研究和期刊評(píng)估。之后中科院分區(qū)逐步發(fā)展成為了一種評(píng)價(jià)學(xué)術(shù)期刊質(zhì)量的重要工具。

歷年中科院分區(qū)趨勢(shì)圖

JCR分區(qū)Trials JCR分區(qū)

2023-2024 年最新版

按JIF指標(biāo)學(xué)科分區(qū)	收錄子集	分區(qū)	排名	百分位
學(xué)科：MEDICINE, RESEARCH & EXPERIMENTAL	SCIE	Q3	122 / 189	35.7%

按JCI指標(biāo)學(xué)科分區(qū)	收錄子集	分區(qū)	排名	百分位
學(xué)科：MEDICINE, RESEARCH & EXPERIMENTAL	SCIE	Q3	122 / 189	35.71%

JCR分區(qū)的優(yōu)勢(shì)在于它可以幫助讀者對(duì)學(xué)術(shù)文獻(xiàn)質(zhì)量進(jìn)行評(píng)估。不同學(xué)科的文章引用量可能存在較大的差異，此時(shí)單獨(dú)依靠影響因子(IF)評(píng)價(jià)期刊的質(zhì)量可能是存在一定問(wèn)題的。因此，JCR將期刊按照學(xué)科門類和影響因子分為不同的分區(qū)，這樣讀者可以根據(jù)自己的研究領(lǐng)域和需求選擇合適的期刊。

歷年影響因子趨勢(shì)圖

發(fā)文數(shù)據(jù)

2023-2024 年國(guó)家/地區(qū)發(fā)文量統(tǒng)計(jì)

國(guó)家/地區(qū)數(shù)量
England1001
USA508
CHINA MAINLAND378
GERMANY (FED REP GER)235
Scotland217
Canada215
Netherlands205
Australia198
France155
Switzerland122

本刊中國(guó)學(xué)者近年發(fā)表論文

1、Effects of prebiotic supplement on gut microbiota, drug bioavailability, and adverse effects in patients with colorectal cancer at different primary tumor locations receiving chemotherapy: study protocol for a randomized clinical trial
Author: Chen, Ya; Liao, Xiaowei; Li, Yanmin; Cao, Hong; Zhang, Feng; Fei, Bojian; Bao, Chuanqing; Cao, Huaxiang; Mao, Yong; Chen, Xiaoping; Gao, Xiang; Zhao, Wei; Xu, Jianmin

Journal: TRIALS. 2023; Vol. 24, Issue 1, pp. -. DOI: 10.1186/s13063-023-07137-y
2、Postoperative awake prone position in geriatric patients with hip fractures: a protocol for a randomized controlled trial on the efficacy of postoperative prone position in reducing pulmonary complications and improving oxygenation
Author: Gao, Yu-cheng; Shi, Liu; Zhang, Yuan-wei; Gao, Wang; Tian, Xie; Cao, Mu-min; Li, Ying-juan; Chen, Hui; Rui, Yun-feng

Journal: TRIALS. 2023; Vol. 24, Issue 1, pp. -. DOI: 10.1186/s13063-023-07308-x
3、Effectiveness and safety of Daixie Decoction granules combined with metformin for the treatment of T2DM patients with obesity: study protocol for a randomized, double-blinded, placebo-controlled, multicentre clinical trial
Author: Liu, Zhidong; Zhang, Kepei; Zhang, Jianpin; Wang, Fei; Zhou, Yang; Wang, Lin; Wang, Miao; Zhang, Yi; Zhou, Shigao

Journal: TRIALS. 2023; Vol. 24, Issue 1, pp. -. DOI: 10.1186/s13063-023-07301-4
4、Effects of Qingda granule on patients with grade 1 hypertension at low-medium risk: study protocol for a randomized, controlled, double-blind clinical trial
Author: Long, Lin-zi; Chu, Jian-feng; Qu, Hua; Yang, Qiao-ning; Lu, Yan; Fu, Chang-geng; Peng, Jun; Chen, Ke-ji

Journal: TRIALS. 2023; Vol. 24, Issue 1, pp. -. DOI: 10.1186/s13063-022-07006-0
5、Efficacy and safety of GLucocorticoid injections into InfrapaTellar faT pad in patients with knee ostEoarthRitiS: protocol for the GLITTERS randomized controlled trial
Author: Zhang, Yan; Ruan, Guangfeng; Zheng, Peng; Huang, Sili; Zhou, Xiaoni; Liu, Xuelian; Hu, Wenjie; Feng, Huiting; Lin, Yangyang; He, Juanjuan; Wei, Zhenhai; Zhang, Jiangshan; Chang, Qing; Wei, Xiaomei; Fan, Tao; Jiang, Li; Ding, Changhai

Journal: TRIALS. 2023; Vol. 24, Issue 1, pp. -. DOI: 10.1186/s13063-022-06993-4
6、Comparison of high-flow nasal cannula and conventional oxygen therapy for high-risk patients during bronchoscopy examination: protocol for a randomized controlled trial
Author: Qin, Hao; Jing, Guo-Qiang; Tan, Wei; Wang, Jun; Yin, Yi-Nan; Chen, Rong-Zhang; Zhang, Wei; Li, Jie

Journal: TRIALS. 2023; Vol. 24, Issue 1, pp. -. DOI: 10.1186/s13063-022-07001-5
7、Esketamine-based opioid-free anaesthesia alleviates postoperative nausea and vomiting in patients who underwent laparoscopic surgery: study protocol for a randomized, double-blinded, multicentre trial
Author: Chen, Hai-yan; Meng, Xiao-yan; Gao, Hao; Liu, Hui; Qiu, Hai-Bo; Lu, Jun; Song, Jin-Chao

Journal: TRIALS. 2023; Vol. 24, Issue 1, pp. -. DOI: 10.1186/s13063-022-07003-3
8、Routine administration of neostigmine after recovery of spontaneous breathing versus neuromuscular monitor-guided administration of neostigmine in pediatric patients: a parallel, randomized, controlled study
Author: Yang, Lei; Hu, Na; Chang, Hong; Yang, Di; Zuo, Yunxia

Journal: TRIALS. 2023; Vol. 24, Issue 1, pp. -. DOI: 10.1186/s13063-023-07066-w